{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:06:33Z","timestamp":1788703593118,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.thromres.2024.04.007","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T11:17:56Z","timestamp":1714562276000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Anticoagulation in COVID-19 patients \u2013 An updated systematic review and meta-analysis"],"prefix":"10.1016","volume":"238","author":[{"given":"Stefanie","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amon","family":"Faske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kranke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Meybohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2024.04.007_bb0005","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00133-20","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systemic infection","volume":"34","author":"Synowiec","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.thromres.2024.04.007_bb0010","series-title":"S3-Leitlinie - Empfehlungen zur station\u00e4ren Therapie von Patienten mit COVID-19","author":"Kluge","year":"2022"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.007_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jcm11010057","article-title":"Safety and efficacy of intermediate- and therapeutic-dose anticoagulation for hospitalised patients with COVID-19: a systematic review and meta-analysis","volume":"11","author":"Reis","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.thromres.2024.04.007_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2022.09.001","article-title":"Anticoagulation in COVID-19 patients - an updated systematic review and meta-analysis","volume":"219","author":"Reis","year":"2022","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.007_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.thromres.2024.04.007_bb0030","author":"Joint Formulary Committee"},{"key":"10.1016\/j.thromres.2024.04.007_bb0035","author":"Rote-Liste-Service-GmbH"},{"key":"10.1016\/j.thromres.2024.04.007_bb0040","series-title":"NICE Guideline 186. November 20, 2020","article-title":"COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19","author":"National Institute for Health and Care Excellence","year":"2020"},{"issue":"17","key":"10.1016\/j.thromres.2024.04.007_bb0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors Jm BMM","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.007_bb0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.007_bb0055","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2024.04.007_bb0060","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 61 (Updated September 2020) Cochrane","article-title":"Chapter 5: collecting data","author":"Li","year":"2020"},{"key":"10.1016\/j.thromres.2024.04.007_bb0065","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2024.04.007_bb0070","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 61 (Updated September 2020) Cochrane","article-title":"Chapter 8: assessing risk of bias in a randomized trial","author":"Higgins","year":"2020"},{"key":"10.1016\/j.thromres.2024.04.007_bb0075","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 61 (Updated September 2020) Cochrane","article-title":"Chapter 10: analysing data and undertaking meta-analyses","author":"Deeks","year":"2020"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.007_bb0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.thromres.2024.04.007_bb0085","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 62 (Updated February 2021)","article-title":"Chapter 14: completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2021"},{"key":"10.1016\/j.thromres.2024.04.007_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab813","article-title":"Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019","volume":"75","author":"Ananworanich","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.thromres.2024.04.007_bb0100","article-title":"Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial","volume":"60","author":"Avezum A OJHA","year":"2023","journal-title":"Eclinicalmedicine"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00175-2","article-title":"Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"9","author":"Barco","year":"2022","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.007_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/a-1485-2372","article-title":"Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial","volume":"122","author":"Bikdeli","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.007_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12712","article-title":"Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: the Swiss COVID-HEP randomized clinical trial","volume":"6","author":"Blondon","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.007_bb0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1161\/CIRCULATIONAHA.122.061533","article-title":"Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT","volume":"146","author":"Bohula Ea BDD","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.007_bb0125","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2352-3026(22)00173-9","article-title":"Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial","volume":"9","author":"Cools","year":"2022","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2024.04.007_bb0130","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.thromres.2024.04.007_bb0135","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"Sadeghipour","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.thromres.2024.04.007_bb0140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.007_bb0145","first-page":"937","article-title":"Effects of standard-dose prophylactic, high-dose prophylactic, and therapeutic anticoagulation in patients with hypoxemic COVID-19 pneumonia: the ANTICOVID randomized clinical trial","volume":"6","author":"Labbe","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.thromres.2024.04.007_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)","volume":"196","author":"Lemos","year":"2020","journal-title":"Thromb. Res."},{"issue":"10291","key":"10.1016\/j.thromres.2024.04.007_bb0155","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2024.04.007_bb0160","article-title":"Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial","volume":"122","author":"Marcos-Jubilar","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.007_bb0165","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1016\/j.sapharm.2022.07.004","article-title":"Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: a comparative study","volume":"18","author":"Mohamed","year":"2022","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13735","article-title":"Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 Randomized Trial","volume":"52","author":"Morici","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"issue":"19","key":"10.1016\/j.thromres.2024.04.007_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11195632","article-title":"Efficacy and safety of tinzaparin in prophylactic, intermediate and therapeutic doses in non-critically ill patients hospitalized with COVID-19: The PROTHROMCOVID randomized controlled trial","volume":"11","author":"Munoz-Rivas","year":"2022","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.007_bb0180","article-title":"Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of COVID-19-associated coagulopathy","volume":"11","author":"Oliynyk","year":"2021","journal-title":"Life (Basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.thromres.2024.04.007_bb0185","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial","volume":"19","author":"Perepu","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"25","key":"10.1016\/j.thromres.2024.04.007_bb0190","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.123.063901","article-title":"Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial","volume":"147","author":"Piazza","year":"2023","journal-title":"Circulation"},{"issue":"10319","key":"10.1016\/j.thromres.2024.04.007_bb0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti E BAL","year":"2022","journal-title":"Lancet (Lond. Engl.)"},{"issue":"11","key":"10.1016\/j.thromres.2024.04.007_bb0200","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00392-023-02240-1","article-title":"Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial","volume":"112","author":"Rauch-Krohnert","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.thromres.2024.04.007_bb0205","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.007_bb0210","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos Ac","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.007_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2023.02.041","article-title":"Randomized trial of anticoagulation strategies for noncritically ill patients hospitalized with COVID-19","volume":"81","author":"Stone","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.04.007_bb0220","series-title":"Apixaban Following Discharge in Hospitalised Adults With COVID-19: Preliminary Results From a Multicentre, Open-Label, Randomised Controlled Platform Clinical Trial","author":"Toshner","year":"2022"},{"key":"10.1016\/j.thromres.2024.04.007_bb0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2022.10.021","article-title":"Ovid investigators. Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial","volume":"221","author":"Voci","year":"2023","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.007_bb0230","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/M22-3350","article-title":"Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization","volume":"176","author":"Wang Ty WAS","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2024.04.007_bb0235","author":"World Health Organization"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.007_bb0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5694\/mja2.52044","article-title":"Australian National Clinical Evidence Taskforce COVID-19 drug treatment guidelines: challenges of producing a living guideline","volume":"219","author":"Barber","year":"2023","journal-title":"Med. J. Aust."},{"issue":"10329","key":"10.1016\/j.thromres.2024.04.007_bb0245","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(22)00109-X","article-title":"Decoupling of omicron variant infections and severe COVID-19","volume":"399","author":"Madhi","year":"2022","journal-title":"Lancet"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:39:16Z","timestamp":1716007156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"alternative-id":["S0049384824001208"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in COVID-19 patients \u2013 An updated systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}